Introduction
============

Liver cancer is one of the most frequent malignant tumors occurring in China; besides, it has emerged as the third leading cause of cancer death in China.[@b1-cmar-10-5313] According to cancer statistics in China in 2015, liver cancer is most frequently observed in males as well as in rural areas. Moreover, the temporal tendency of incidence rates in liver cancer is decreased.[@b1-cmar-10-5313] The histological type of most primary liver cancers is hepatocellular carcinoma (HCC).[@b2-cmar-10-5313] Hepatitis B virus (HBV) infection is identified as a risk factor for HCC, especially in China, where the infection rate of HBV is quite high. HBV is a single-stranded DNA virus, which can be integrated into the host genome, subsequently may activate the cellular proto-oncogenes or suppress growth-regulating genes in cis,[@b3-cmar-10-5313] and induce chromosomal instability or insertional mutations.[@b4-cmar-10-5313] HBV-induced DNA damage is one of the potential mechanisms that contribute to the hepatocarcinogenesis of HCC.[@b5-cmar-10-5313]

The excision repair cross-complementation (ERCC) genes include *ERCC1*, *ERCC2*, *ERCC3*, *ERCC4*, *ERCC5*, *ERCC6*, and *ERCC8*, constituting a set of proteins that are involved in DNA repair. Nucleotide excision repair (NER) is considered as an extensively pivotal excision mechanism, which removes DNA damage caused by various kinds factors, and a key DNA repair pathway in eukaryotic cells, whereas the ERCC genes constitute the key genes in the NER pathway.[@b6-cmar-10-5313],[@b7-cmar-10-5313] As revealed by the investigations, the genetic variation or mutation of the NER pathway genes is likely to impact the cancer risk by affecting the DNA repair efficacy, and some nonsynonymous coding single-nucleotide polymorphisms or mutations in DNA repair genes or their regulatory sequences induce the phenotypic changes and are involved in cancer development.[@b8-cmar-10-5313] Previous reports of the ERCC genes, suggesting they were associated with multiple cancer prognoses,[@b9-cmar-10-5313]--[@b12-cmar-10-5313] and polymorphisms of the ERCC genes also have significant association with the HCC development, progression, survival, and cancer susceptibility.[@b5-cmar-10-5313],[@b13-cmar-10-5313]--[@b15-cmar-10-5313] However, the systematic investigation of the diagnostic and prognostic values of the expression level of ERCC genes in HCC continue to be unclear. Therefore, the aim of the present study was to use the whole genome expression data set from the Gene Expression Omnibus (GEO; <https://www.ncbi.nlm.nih.gov/geo/>) public database for the purpose of systematically investigating the diagnostic and prognostic values of ERCC genes in HBV-related HCC.

Materials and methods
=====================

Data processing
---------------

In order to perform the present study, the inclusion criteria of public data set were set as follows: 1) the patients were HBV-related HCC; 2) the information of clinical outcome and features should be available; and 3) the data are the whole genome expression profile data. Through the retrieval of the public database, only the data set of GSE14520 caters to the inclusion criteria. GSE14520 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520>; accessed May 13, 2018), a data set from the GEO public database, was included in the present study. Calculation of the expression profile chip data set of GSE14520 was carried out with the use of the match probes package in the R platform; subsequent to that, the robust multi-array average (RMA) method in the R affy package was used to obtain probe set expression summaries.[@b16-cmar-10-5313],[@b17-cmar-10-5313] Details of the experiment protocols and data processing are available at <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM362992>. Moreover, just the data set of the Affymetrix HT Human Genome U133A Array (platform GPL3921) was included in the current study to avoid the batch effect. These patients having a clearly HBV infection were included in the current study, and those patients without complete prognostic information and other clinical features were excluded. Owing to the fact that the population included in the current study originates from the public databases and the present study does not contain any studies performed by any of the authors with human participants or animals, there is no need for approval by additional ethics committees.

Expression distribution and survival analysis of ERCC genes
-----------------------------------------------------------

Investigation of the expression distribution of ERCC genes was carried out with the help of the independent samples *t*-test and the Metabolic gEne RApid Visualizer (MERAV, <http://merav.wi.mit.edu/>, accessed May 13, 2018) online tool.[@b18-cmar-10-5313] Receiver-operating characteristic (ROC) curves were put to use for the investigation of the potential application values in distinct HBV-related HCC tumors and adjacent normal liver tissues. The Kaplan--Meier method, with a log-rank test, and the univariate and multivariate Cox proportional hazards regression models were employed for the purpose of comparing the prognosis between different groups. Stratified analysis was employed for the assessment of the prognostic values of prognostic ERCC genes in different strata of HBV-related HCCs. Joint effect survival analyses between prognostic ERCC genes and serum alpha-fetoprotein (AFP), which is a recognized prognostic biomarker in HCC, have also been carried out for investigating the combined effect on HCC prognosis prediction. The high- and low-expression groups of the ERCC family genes were cutoff in accordance with the median values.[@b19-cmar-10-5313]--[@b22-cmar-10-5313]

Nomogram construction
---------------------

To investigate the individualized prognostic prediction and evaluation system, we also developed a nomogram for the evaluation of the prognostic risk of each patient, which was based on the prognostic clinical indicators and prognostic-related ERCC genes of Cox regression model. Besides that, evaluation of the nomogram was using the concordance index (c-index). The nomogram was carried out by an *rms* package (<https://CRAN.R-project.org/package=rms>), together with its dependent packages in the R platform, with visualization using *gplots*.[@b23-cmar-10-5313],[@b24-cmar-10-5313]

Gene set enrichment analysis (GSEA)
-----------------------------------

In a bid to figure out the potential mechanism of prognostic-related ERCC genes participating in the HBV-related HCC prognosis, we further performed a GSEA (<http://software.broadinstitute.org/gsea/index.jsp>) to discover the potential biological processes and pathways involved in the different expression levels of ERCC genes.[@b25-cmar-10-5313],[@b26-cmar-10-5313] The Molecular Signatures Database of GSEA used the c2 (c2. all.v6.1.symbols.gmt) and c5 (c5.all.v6.1.symbols.gmt) reference gene sets.[@b27-cmar-10-5313] Results with a *P*-value below 0.05 and false discovery rate (FDR) below 0.25 were considered statistically significant.

Coexpression analysis
---------------------

To further evaluate the function of *ERCC8* in HBV-related HCC, we further carried out a genome-wide coexpression analysis of *ERCC8* in the HBV-related HCC of the GSE14520 cohort. The Pearson's correlation coefficient was used to evaluate the coexpression genes, and the Database for Annotation, Visualization and Integrated Discovery (DAVID; <https://david.ncifcrf.gov/home.jsp>, accessed May 13, 2018) v6.8[@b28-cmar-10-5313],[@b29-cmar-10-5313] was used for the purpose of functional assessment.

Statistical analysis
--------------------

FDR in the GSEA was used to estimate the probability that the normalized enrichment score represents a false-positive finding, which was calculated with the help of the Benjamini and Hochberg method. A *P*-value \<0.05 was regarded as statistically significant. All the statistical analyses were performed using SPSS v20.0 (IBM Corporation, Armonk, NY, USA) and R3.3.1 (<https://www.r-project.org/>).

Results
=======

Study population
----------------

A total of 212 HBV-related HCC patients were included in the present study, coupled with 204 adjacent normal liver tissue specimens. Both the demographic and clinical features have been presented in [Table 1](#t1-cmar-10-5313){ref-type="table"}. The clinical features including gender, cirrhosis, Barcelona Clinic Liver Cancer (BCLC) stage, TNM stage, and Cancer of the Liver Italian Program (CLIP) stage were significantly associated with the recurrence-free survival (RFS) of the HBV-related HCC, whereas the clinical features including cirrhosis, tumor size, BCLC stage, TNM stage, CLIP stage, and serum AFP were significantly correlated with overall survival (OS).

Expression distribution and survival analysis of ERCC genes
-----------------------------------------------------------

Through the comparison of the expression of ERCC genes in the HBV-related HCC tumor tissues and adjacent normal liver tissues, we observed that *ERCC1*, *ERCC2*, *ERCC3*, and *ERCC8* were significantly upregulated in the HBV-related HCC tumor tissues, whereas *ERCC4* and *ERCC5* were significantly downregulated in the HBV-related HCC tumor tissues ([Figure 1](#f1-cmar-10-5313){ref-type="fig"}). These dysregulated genes are also observable in liver cancer using the MERAV online tool ([Figure 2A--G](#f2-cmar-10-5313){ref-type="fig"}). Thereafter, we performed the investigation of the potential application values of the ERCC genes in distinguishing the HBV-related HCC tumor tissues and adjacent normal liver tissues using the ROC curve. As the ROC analysis suggests, six ERCC genes (*ERCC1*, *ERCC2*, *ERCC3*, *ERCC4*, *ERCC5*, and *ERCC8*) could be a biomarker used to distinguish between HBV-related HCC tumor tissues and the adjacent normal liver tissues; the area under the curve of the ROC was in the range between 0.623 and 0.744 ([Figure 3A--G](#f3-cmar-10-5313){ref-type="fig"}).

Survival analysis of ERCC family genes has been presented in [Figures 4A--G](#f4-cmar-10-5313){ref-type="fig"} and [5A--G](#f5-cmar-10-5313){ref-type="fig"}; these findings provide the demonstration that the high *ERCC8* expression significantly reduced the risk of recurrence (adjusted *P*=0.021; HR=0.643; 95% CI=0.442--0.937, [Table 2](#t2-cmar-10-5313){ref-type="table"}, [Figure 4G](#f4-cmar-10-5313){ref-type="fig"}) and death (adjusted *P*=0.049; HR=0.631; 95% CI=0.399--0.998, [Table 2](#t2-cmar-10-5313){ref-type="table"}, [Figure 5G](#f5-cmar-10-5313){ref-type="fig"}) in the HBV-related HCC. Stratification analysis was also used to assess the prognostic values of *ERCC8* in the HBV-related HCC. The high expression of *ERCC8* significantly reduced the risk of recurrence in the patients having cirrhosis, serum AFP \>300 ng/mL, single nodules, and in the male patients ([Table 3](#t3-cmar-10-5313){ref-type="table"}), whereas the high expression of *ERCC8* significantly reduced the risk of death in the patients having single nodules, together with the male patients ([Table 3](#t3-cmar-10-5313){ref-type="table"}). The joint effect survival analysis of *ERCC8* and serum AFP suggests that the patients with high *ERCC8* expression and a serum AFP ≤300 ng/mL (adjusted *P*=0.035; HR=0.583; 95% CI=0.354--0.962, [Table 4](#t4-cmar-10-5313){ref-type="table"}, [Figure 6A](#f6-cmar-10-5313){ref-type="fig"}) or \>300 ng/mL (adjusted *P*=0.004; HR=0.426; 95% CI=0.237--0.768, [Table 4](#t4-cmar-10-5313){ref-type="table"}, [Figure 6A](#f6-cmar-10-5313){ref-type="fig"}) showed a significantly decreased risk of recurrence in the HBV-related HCC compared with patients having AFP \>300 ng/mL and low *ERCC8* expression. In contrast, the patients with high *ERCC8* expression and AFP ≤300 ng/mL showed a significantly reduced risk of death in the HBV-related HCC (adjusted *P*=0.028; HR=0.499; 95% CI=0.268--0.927, [Table 4](#t4-cmar-10-5313){ref-type="table"}, [Figure 6B](#f6-cmar-10-5313){ref-type="fig"}) compared with patients having AFP \>300 ng/mL and low *ERCC8* expression.

Thereafter, we also performed the verification of these joint effect survival analyses between *ERCC8* and AFP mRNA expression level and demonstrated that the *AFP* mRNA expression also performed well in the HCC prognosis prediction. Patients with high *ERCC8* expression and low (adjusted *P*=0.003; HR=0.443; 95% CI=0.259--0.757, [Table 4](#t4-cmar-10-5313){ref-type="table"}, [Figure 6C](#f6-cmar-10-5313){ref-type="fig"}) or high (adjusted *P*=0.002; HR=0.418; 95% CI=0.238--0.734, [Table 4](#t4-cmar-10-5313){ref-type="table"}, [Figure 6C](#f6-cmar-10-5313){ref-type="fig"}) *AFP* level showed a significantly decreased risk of recurrence in the HBV-related HCC compared with patients who had high *AFP* and low *ERCC8* expression, as well as in patients with low *AFP* and *ERCC8* expression (adjusted *P*=0.004; HR=0.425; 95% CI=0.238--0.757, [Table 4](#t4-cmar-10-5313){ref-type="table"}, [Figure 6C](#f6-cmar-10-5313){ref-type="fig"}). With respect to OS, we observed that the patients with high *ERCC8* expression and low *AFP* expression showed a significantly reduced risk of death in the HBV-related HCC (adjusted *P*=0.035; HR=0.487; 95% CI=0.249--0.952, [Table 4](#t4-cmar-10-5313){ref-type="table"}, [Figure 6D](#f6-cmar-10-5313){ref-type="fig"}) compared with patients who had high *AFP* and low *ERCC8* expression.

Nomogram construction
---------------------

Thereafter, we performed the investigation of the potential application of *ERCC8* mRNA expression in the individual-ized prognosis prediction. Those clinical features that were significantly correlated to RFS or OS were included in the development of nomogram for RFS and OS, correspondingly. The nomogram of the HBV-related HCC RFS was developed in accordance with the gender, cirrhosis, TMN stage, BCLC stage, CLIP stage, and *ERCC8* expression (c-index \[95% CI\]=0.68 \[0.63--0.74\], [Figure 7A](#f7-cmar-10-5313){ref-type="fig"}), whereas the nomogram of HBV-related HCC OS was developed by tumor size, cirrhosis, TMN stage, BCLC stage, CLIP stage, AFP, and *ERCC8* expression (c-index \[95% CI\]=0.72 \[0.66--0.79\], [Figure 7B](#f7-cmar-10-5313){ref-type="fig"}). In accordance with the nomogram for RFS and OS, we observed that the contribution of *ERCC8* expression in the HBV-related HCC prognosis prediction was lower compared with some conventional clinical indicators; however, the expression of *ERCC8* contributed much more than the serum AFP in the nomogram of the HBV-related HCC OS ([Figure 7B](#f7-cmar-10-5313){ref-type="fig"}).

GSEA of *ERCC8*
---------------

Investigation by GSEA using the c2 reference gene set indicates that the high expression of *ERCC8* was significantly enriched in the NF-kappa-B and Wnt signaling pathway, as well as the P53 independent G1-S DNA damage checkpoint, TCA cycle and respiratory electron transport, and oxidative phosphorylation ([Figure 8A--F](#f8-cmar-10-5313){ref-type="fig"}, [Table S1](https://www.dovepress.com/get_supplementary_file.php?f=179043.xlsx)). GSEA with c5 indicates that the high expression of *ERCC8* was significantly correlated to metabolically related biological processes, for instance, nucleoside triphosphate and cellular amine metabolic processes, and the generation of precursor metabolites and energy ([Figure 8G--I](#f8-cmar-10-5313){ref-type="fig"}, [Table S2](https://www.dovepress.com/get_supplementary_file.php?f=179043.xlsx)). In comparison, using the results of the c2 and c5 reference gene set, we observed that the high expression of *ERCC8* may be involved in energy metabolism biological processes, which may have an impact on the prognosis of the HBV-related HCC.

Genome-wide coexpression analysis and function assessment of *ERCC8*
--------------------------------------------------------------------

For the purpose of further exploring the function of *ERCC8* in the HBV-related HCC, a genome-wide coexpression analysis was carried out. With respect to the multiple probes corresponding to one gene, we used the mean values of multiple probes to present the expression values of this gene in a genome-wide coexpression analysis. A total of 273 genes with \|Pearson's correlation coefficient\|\>0.4 and *P*\<0.05 were taken into consideration as coexpressed with *ERCC8* in the HBV-related HCC ([Figure 9](#f9-cmar-10-5313){ref-type="fig"}, [Table S3](https://www.dovepress.com/get_supplementary_file.php?f=179043.xlsx)). Thereafter, the functional assessment of the *ERCC8*-coexpressed genes was performed using DAVID v6.8. Gene Ontology (GO) term analysis suggested that *ERCC8* and its coexpressed genes together are significantly enriched in the MAPK cascade, damaged DNA binding, DNA synthesis involved in DNA repair, and DNA damage checkpoints ([Figure 10](#f10-cmar-10-5313){ref-type="fig"}). In contrast, the Kyoto Encyclopedia of Genes and Genomes suggested that *ERCC8* and its coexpressed genes were significantly enriched in the ribosome-signaling pathway (hsa03010, *P*=0.003, gene count=8).

Discussion
==========

Through the review of the literature, we observed that extensive previous studies have focused on the investigation of the association between the ERCC gene polymorphisms and the risk of cancers[@b30-cmar-10-5313],[@b31-cmar-10-5313] or on the ERCC gene polymorphisms and cancer prognosis.[@b32-cmar-10-5313],[@b33-cmar-10-5313] Besides that, the ERCC gene polymorphisms have also been reported for having correlation with the prognosis of patients treated with chemotherapy.[@b34-cmar-10-5313]--[@b37-cmar-10-5313] However, there are rare reports of the systematic investigations of the expression of ERCC in cancer diagnosis and prognosis.[@b9-cmar-10-5313],[@b38-cmar-10-5313],[@b39-cmar-10-5313]

Previous studies substantiated that polymorphisms in *ERCC2* and *ERCC5* confer susceptibility to the acute myeloid leukemia (AML)[@b40-cmar-10-5313] and that polymorphisms in *ERCC2* and *XPC* were significantly associated with the AML survival.[@b41-cmar-10-5313] Polymorphisms in *ERCC5* also make contribution toward the susceptibility of lung cancer and squamous cell carcinomas of the oropharynx, larynx, and esophagus;[@b42-cmar-10-5313] head and neck;[@b43-cmar-10-5313] prostate cancer;[@b44-cmar-10-5313] HCC;[@b15-cmar-10-5313] and bladder cancer (BC).[@b31-cmar-10-5313] A study performed by Sakano et al also found that the genetic variants of *ERCC5* contribute to the tumor invasiveness in BC.[@b45-cmar-10-5313] In addition, the polymorphisms *ERCC2*-rs1799793 and *ERCC5*-rs17655 may also contribute to the recurrence risk of squamous cell carcinoma of the oropharynx.[@b37-cmar-10-5313]

There have also been reports of the prognostic values of ERCC genetic variants in multiple cancers. An investigation carried out by Liu et al revealed the fact that *ERCC1*-rs11615 is likely to be a useful genetic marker for the prediction of the osteosarcoma prognosis and that the CC genotype is correlated with a better clinical outcome.[@b46-cmar-10-5313] The work performed by Liu et al indicated that the *XRCC1-*399A/A genotype was significantly correlated with a better clinical outcome.[@b47-cmar-10-5313] Previous studies demonstrated that genetic variants of *ERCC2* and *ERCC5* may be the independent prognostic factors in the patients with melanoma[@b32-cmar-10-5313],[@b48-cmar-10-5313] and osteosarcoma.[@b49-cmar-10-5313] In addition, polymorphisms of *ERCC5* were also correlated with the response to chemotherapy and the prognosis of osteosarcoma.[@b50-cmar-10-5313],[@b51-cmar-10-5313] Furthermore, polymorphisms of *ERCC5* have also been reported to have an influence in multiple cancer prognosis, such as lung cancer,[@b33-cmar-10-5313],[@b47-cmar-10-5313] and colorectal cancer (CRC).[@b52-cmar-10-5313],[@b53-cmar-10-5313]

The interindividual differences in the patients treated with chemotherapy mainly affected the efficiency of the DNA damage--repair system in the cells and then affected the clinical outcomes. Extensive studies have demonstrated that the ERCC genes were involved in the responses to chemotherapy and the prognosis of the patients with CRC[@b36-cmar-10-5313],[@b54-cmar-10-5313]--[@b56-cmar-10-5313] as well as advanced non-small cell lung cancer (NSCLC).[@b57-cmar-10-5313],[@b58-cmar-10-5313] The *ERCC5* polymorphism His46His was reported to be associated with the susceptibility of platinum-based chemotherapy in the advanced NSCLC[@b35-cmar-10-5313] and significantly affected clinical outcomes.[@b58-cmar-10-5313] The *ERCC5* promoter polymorphism rs751402 was significantly associated with the chemotherapy response in the advanced NSCLC, and the AA genotype may contribute to increase the effect of chemotherapy response.[@b59-cmar-10-5313] Hu et al substantiated that the rs2296147 T allele and rs873601 G allele were associated with the better progression-free survival (PFS) and OS in the advanced NSCLC patients undergoing the platinum-based chemotherapy[@b57-cmar-10-5313]; furthermore, the results of the rs2296147 T allele in OS of the advanced NSCLC patients undergoing platinum-based chemotherapy are also verifiable in another cohort.[@b60-cmar-10-5313] However, the rs1047768 TT genotype, which showed a significantly shortened median PFS and OS in the advanced NSCLC patients undergoing platinum-based chemotherapy in the study of Zhang et al,[@b60-cmar-10-5313] is unable to be verified in the cohort collected by Hu et al.[@b57-cmar-10-5313] With respect to the ERCC genetic variation in CRC response to platinum-based chemotherapy and therapeutic outcomes, multiple studies demonstrated that the *ERCC5* polymorphisms may have an impact on the susceptibility and therapeutic outcomes to the colorectal cancer patients, who received oxaliplatin chemotherapy.[@b36-cmar-10-5313],[@b54-cmar-10-5313]--[@b56-cmar-10-5313]

By reviewing the above literature, we found that a considerable amount of literature has been published on the genetic variation of ERCC genes in cancer susceptibility, prognosis, and therapeutic outcomes; however, the expression of ERCC genes in cancer diagnostic and prognostic values were rarely mentioned. Several investigations verified the fact that the low expression of ERCC1 was significantly correlated with a better clinical outcome in patients with breast cancer,[@b38-cmar-10-5313] NSCLC,[@b61-cmar-10-5313] and ovarian cancer,[@b9-cmar-10-5313] as well as in advanced NSCLC treated with platinum-based chemotherapy.[@b10-cmar-10-5313] A systematic investigation of the ERCC genes in the ovarian cancer prognosis was carried out by Zhao et al using the Kaplan--Meier Plotter online tool and revealed that the high expression of *ERCC8* and *ERCC1* had correlations with a poor OS, whereas the high expression of *ERCC4* was associated with a better OS.[@b9-cmar-10-5313] In our current study, we observed that the high expression of *ERCC8* was significantly correlated with a better RFS and OS in the HBV-related HCC after hepatectomy, and our current study was the first to investigate the potential prognostic application values of *ERCC8* in the HBV-related HCC. Comprehensive survival analysis of stratification analysis and joint effect survival analysis indicates that *ERCC8* may be served as an independent prognostic indicator for the HBV-related HCC; the nomograms indicate that the combination of *ERCC8* and traditional prognostic indicators may have an application value in the individualized prognosis prediction. It is worth noting that the results of *ERCC8* obtained in our current study were contradictory to the results of the study carried out by Zhao et al in the ovarian cancer prognosis.[@b9-cmar-10-5313] The possible causes of the above inconsistency results suggested that the survival analysis in the study by Zhao et al was derived from the Kaplan--Meier method, which was a univariate survival analysis and that the results obtained from such kinds of statistical methods may be unreliable. However, the key advantage of the results of the current study was assessed by a multivariate Cox proportional hazards regression model, and the statistical method was more reliable than the Kaplan--Meier method in survival analysis. Another possible reason may be that *ERCC8* plays different roles in both the ovarian cancer and HBV-related HCC. However, these results still require to be further verified in a larger sample, and the hypotheses also need further experimental validation.

The current study has some limitations that need to clarification. First, since the data set is from the public database, the clinical information in the GSE14520 was constrained. Consequently, we are incapable of attaining complete clinical information with which to carry out a comprehensive prognostic analysis; the incomplete clinical information, such as postoperative treatment, may influence prognosis. Second, the raw values of serum AFP level in GSE14520 were not provided as well, accordingly, we were unable to carry out a joint effect survival analysis in the serum with an AFP cutoff 400 ng/mL, which is a recognized cutoff value. Third, through the retrieval of the public database, only the GSE14520 data set caters to the requirements of the current study. That is why the results of the present study are derived from a single cohort, and additional cohorts to verify the results are needed.

Despite these limitations, our current study is the first to systematically investigate the diagnostic and prognostic values of ERCC genes in the HBV-related HCC. As our findings suggest, the dysregulated ERCC genes may have a potential application in the HBV-related HCC diagnosis and *ERCC8* may be a potential novel indicator for the HBV-related HCC prognosis prediction. We also developed two nomograms for the individualized prognosis prediction and investigated the potential mechanisms and functions of *ERCC8* in the HBV-related HCC using the GSEA and genome-wide coexpression analysis approaches.

Conclusion
==========

The present study indicates that six ERCC genes (*ERCC1*, *ERCC2*, *ERCC3*, *ERCC4*, *ERCC5*, and *ERCC8*) were dysregulated between the HBV-related HCC tumor and paracancerous tissues, and mRNA expression of *ERCC8* may act as a potential biomarker for the HBV-related HCC prognosis.
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![Gene expression distribution of ERCC genes in GSE14520 HBV-related HCC cohort.\
**Notes:** \*\*\**P*\<0.001; \*\*\*\**P*\<0.0001.\
**Abbreviations:** ERCC, excision repair cross-complementation; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.](cmar-10-5313Fig1){#f1-cmar-10-5313}

![Gene expression distribution of ERCC gene in liver cancer using the MERAV.\
**Note:** The order of box plots of ERCC genes were as follows: *ERCC1* (**A**), *ERCC2* (**B**), *ERCC3* (**C**), *ERCC4* (**D**), *ERCC5* (**E**), *ERCC6* (**F**), and *ERCC8* (**G**).\
**Abbreviations:** ERCC, excision repair cross-complementation; MERAV, Metabolic gEne RApid Visualizer.](cmar-10-5313Fig2){#f2-cmar-10-5313}

![ROC curves of ERCC genes in distinguish HBV-related HCC tissue from adjacent normal liver tissue.\
**Note:** The order of ROC curves of ERCC genes were as follows: *ERCC1* (**A**), *ERCC2* (**B**), *ERCC3* (**C**), *ERCC4* (**D**), *ERCC5* (**E**), *ERCC6* (**F**), and *ERCC8* (**G**).\
**Abbreviations:** AUC, area under the curve of ROC; ERCC, excision repair cross-complementation; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; ROC, receiver-operating characteristic.](cmar-10-5313Fig3){#f3-cmar-10-5313}

![Kaplan--Meier curves of ERCC genes in HBV-related HCC RFS.\
**Note:** The order of Kaplan--Meier curves of ERCC genes were as follows: *ERCC1* (**A**), *ERCC2* (**B**), *ERCC3* (**C**), *ERCC4* (**D**), *ERCC5* (**E**), *ERCC6* (**F**), and *ERCC8* (**G**).\
**Abbreviations:** ERCC, excision repair cross-complementation; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; RFS, recurrence-free survival.](cmar-10-5313Fig4){#f4-cmar-10-5313}

![Kaplan--Meier curves of ERCC genes in HBV-related HCC OS.\
**Note:** The order of Kaplan--Meier curves of ERCC genes were as follows: *ERCC1* (**A**), *ERCC2* (**B**), *ERCC3* (**C**), *ERCC4* (**D**), *ERCC5* (**E**), *ERCC6* (**F**), and *ERCC8* (**G**).\
**Abbreviations:** ERCC, excision repair cross-complementation; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; OS, overall survival.](cmar-10-5313Fig5){#f5-cmar-10-5313}

![Joint effect survival analysis of *ERCC8* and AFP in HBV-related HCC prognosis.\
**Notes:** (**A**) RFS stratified by *ERCC8* and serum AFP level; (**B**) OS stratified by *ERCC8* and serum AFP level; (**C**) RFS stratified by *ERCC8* and AFP mRNA level; and (**D**) OS stratified by *ERCC8* and serum AFP mRNA level.\
**Abbreviations:** AFP, alpha-fetoprotein; ERCC, excision repair cross-complementation; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; OS, overall survival; RFS, recurrence-free survival.](cmar-10-5313Fig6){#f6-cmar-10-5313}

![Nomogram for predicting the 1-, 3-, and 5-year event with *ERCC8* expression and clinical indicators.\
**Notes:** (**A**) Nomogram for *ERCC8* expression in HBV-related HCC RFS. (**B**) Nomogram for *ERCC8* expression in HBV-related HCC OS.\
**Abbreviations:** AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; CLIP, Cancer of the Liver Italian Program; ERCC, excision repair cross-complementation; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; OS, overall survival; RFS, recurrence-free survival.](cmar-10-5313Fig7){#f7-cmar-10-5313}

![GSEA results of *ERCC8*.\
**Notes:** (**A)**--**(F**) GSEA results of c2 reference gene sets for high *ERCC8* expression. (**G)**--**(I**) GSEA results of c5 reference gene sets for high *ERCC8* expression.\
**Abbreviations:** ERCC, excision repair cross-complementation; GSEA, gene set enrichment analysis; FDR, false discovery rate; ES, Enrichment Score; NES, Normalized Enrichment Score.](cmar-10-5313Fig8){#f8-cmar-10-5313}

![Coexpression genes of *ERCC8* in HBV-related HCC.\
**Notes:** The green nodes represent negative correlation with *ERCC8*, and the red nodes represent positive correlation with *ERCC8*.\
**Abbreviations:** ERCC, excision repair cross-complementation; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.](cmar-10-5313Fig9){#f9-cmar-10-5313}

![GO term enrichments of coexpression genes of *ERCC8* in HBV-related HCC.\
**Abbreviations:** ERCC, excision repair cross-complementation; GO, Gene Ontology; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.](cmar-10-5313Fig10){#f10-cmar-10-5313}

###### 

Distribution of HCC patients' characteristics and prognosis analysis

  Variables                                                RFS       OS                                                                            
  -------------------------------------------------------- --------- ---- ----------------------- --------- -------- ---- ------------------------ ---------
                                                                                                                                                   
  Age (years)                                                                                     0.916                                            0.629
   ≤60                                                     96/175    46   1                                 69/175   NA   1                        
   \>60                                                    20/37     48   0.974 (0.602--1.578)              13/37    NA   0.864 (0.478--1.564)     
  Gender                                                                                          0.018                                            0.148
   Male                                                    106/183   40   1                                 74/183   NA   1                        
   Female                                                  10/29     NA   0.467 (0.244--0.893)              8/29     NA   0.587 (0.283--1.218)     
  Cirrhosis                                                                                       0.029                                            0.025
   No                                                      5/17           1                                 2/17     NA   1                        
   Yes                                                     111/195   38   2.612 (1.066--6.402)              80/195   NA   4.335 (1.065--17.638)    
  Tumor size[a](#tfn1-cmar-10-5313){ref-type="table-fn"}                                          0.073                                            0.002
   ≤5 cm                                                   73/137    51   1                                 46/137   NA   1                        
   \>5 cm                                                  43/74     28   1.409 (0.966--2.056)              36/74    53   1.975 (1.274--3.060)     
  Multinodular                                                                                    0.381                                            0.052
   Single                                                  90/167    49   1                                 59/167   NA   1                        
   Multiple                                                26/45     28   1.216 (0.785--1.883)              23/45    48   1.607 (0.992--2.604)     
  BCLC stage                                                                                      \<0.001                                          \<0.001
   0                                                       6/20      NA   1                                 2/20     NA   1                        
   A                                                       74/143    51   2.050 (0.892--4.711)              48/143   NA   4.119 (1.001--16.951)    
   B                                                       15/22     27   4.019 (1.550--10.421)             12/22    46   8.992 (2.005--40.320)    
   C                                                       21/27     9    6.163 (2.477--15.333)             20/27    13   18.993 (4.419--81.632)   
  TNM stage                                                                                       \<0.001                                          \<0.001
   I                                                       35/89     NA   1                                 20/89    NA   1                        
   II                                                      48/76     28   1.995 (1.289--3.088)              32/76    NA   2.214 (1.265--3.873)     
   III                                                     33/47     18   3.220 (1.993--5.204)              30/47    18   5.197 (2.930--9.218)     
  CLIP stage                                                                                      0.001                                            \<0.001
   0                                                       46/94     57   1                                 26/94    NA   1                        
   1                                                       37/71     40   1.197 (0.776--1.846)              25/71    NA   1.414 (0.816--2.449)     
   2/3/4/5                                                 33/47     19   2.233 (1.424--3.500)              31/47    27   3.638 (2.153--6.149)     
  Serum AFP[b](#tfn2-cmar-10-5313){ref-type="table-fn"}                                           0.327                                            0.047
   ≤300 ng/mL                                              62/115    48   1                                 39/115   NA   1                        
   \>300 ng/mL                                             54/94     35   1.200 (0.833--1.728)              43/94    NA   1.546 (1.002--2.385)     

**Notes:**

Information of tumor size was unavailable in one patient.

Information of serum AFP was unavailable in three patients.

**Abbreviations:** AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; CLIP, Cancer of the Liver Italian Program; HCC, hepatocellular carcinoma; MRT, median recurrence time; MST, median survival time; OS, overall survival; RFS, recurrence-free survival.

###### 

Survival analysis of ERCC genes in HBV-related HCC prognosis

  Gene expression   Patients (n=212)   MST/MRT (months)   Crude HR (95% CI)      Crude *P*   Adjusted HR (95% CI)   Adjusted *P*[a](#tfn4-cmar-10-5313){ref-type="table-fn"}
  ----------------- ------------------ ------------------ ---------------------- ----------- ---------------------- ----------------------------------------------------------
                                                                                                                    
  **RFS**                              **MRT**                                                                      
  *ERCC1*                                                                                                           
   Low              106                40                 1                                  1                      
   High             106                49                 0.903 (0.627--1.300)   0.583       1.061 (0.723--1.556)   0.762
  *ERCC2*                                                                                                           
   Low              106                35                 1                                  1                      
   High             106                49                 0.854 (0.593--1.229)   0.396       0.934 (0.646--1.351)   0.717
  *ERCC3*                                                                                                           
   Low              106                46                 1                                  1                      
   High             106                46                 1.059 (0.735--1.524)   0.759       1.173 (0.805--1.710)   0.405
  *ERCC4*                                                                                                           
   Low              106                36                 1                                  1                      
   High             106                53                 0.706 (0.489--1.019)   0.063       0.818 (0.560--1.194)   0.298
  *ERCC5*                                                                                                           
   Low              106                41                 1                                  1                      
   High             106                46                 1.066 (0.740--1.535)   0.731       0.952 (0.651--1.392)   0.798
  *ERCC6*                                                                                                           
   Low              106                30                 1                                  1                      
   High             106                54                 0.704 (0.448--1.016)   0.061       0.768 (0.527--1.118)   0.168
  *ERCC8*                                                                                                           
   Low              106                30                 1                                  1                      
   High             106                57                 0.613 (0.424--0.887)   0.009       0.643 (0.442--0.937)   0.021
  **OS**                               **MST**                                                                      
  *ERCC1*                                                                                                           
   Low              106                NA                 1                                  1                      
   High             106                NA                 0.864 (0.560--1.334)   0.509       1.040 (0.663--1.630)   0.865
  *ERCC2*                                                                                                           
   Low              106                NA                 1                                  1                      
   High             106                NA                 0.805 (0.522--1.243)   0.328       0.865 (0.558--1.343)   0.518
  *ERCC3*                                                                                                           
   Low              106                NA                 1                                  1                      
   High             106                NA                 1.303 (0.844--2.012)   0.233       1.511 (0.961--2.375)   0.074
  *ERCC4*                                                                                                           
   Low              106                NA                 1                                  1                      
   High             106                NA                 0.637 (0.410--0.989)   0.044       0.729 (0.465--1.142)   0.167
  *ERCC5*                                                                                                           
   Low              106                NA                 1                                  1                      
   High             106                NA                 1.067 (0.691--1.647)   0.77        0.899 (0.572--1.412)   0.643
  *ERCC6*                                                                                                           
   Low              106                58                 1                                  1                      
   High             106                NA                 0.654 (0.421--1.015)   0.059       0.723 (0.462--1.133)   0.157
  *ERCC8*                                                                                                           
   Low              106                54                 1                                  1                      
   High             106                NA                 0.549 (0.351--0.858)   0.008       0.631 (0.399--0.998)   0.049

**Note:**

Adjustment for age, gender, cirrhosis, tumor size, tumor number, BCLC stage, and serum AFP level.

**Abbreviations:** AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; CLIP, Cancer of the Liver Italian Program; ERCC, excision repair cross-complementation; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; MRT, median recurrence time; MST, median survival time; OS, overall survival; RFS, recurrence-free survival.

###### 

Stratified survival analysis of *ERCC8* in HBV-related HCC prognosis

  Variables                                                Patients (n=218)   Low ERCC8   High ERCC8   RFS                                       OS                                                               
  -------------------------------------------------------- ------------------ ----------- ------------ ----------------------------------------- ------- -------------------------------------------------------- -------
                                                                                                                                                                                                                  
  Age (years)                                                                                                                                                                                                     
   ≤60                                                     175                88          87           0.694 (0.456--1.055)                      0.087   0.659 (0.396--1.098)                                     0.11
   \>60                                                    37                 18          19           0.498 (0.172--1.442)                      0.199   0.506 (0.133--1.926)                                     0.318
  Gender                                                                                                                                                                                                          
   Male                                                    183                91          92           0.664 (0.447--0.984)                      0.041   0.647 (0.398--1.053)                                     0.08
   Female                                                  29                 15          14           0.099 (0.007--1.319)                      0.08    0.140 (0.011--1.844)                                     0.135
  Cirrhosis                                                                                                                                                                                                       
   No                                                      17                 6           11           1×10e^−6^ (1.8×10e^−196^--3.7×10e^183^)   0.952   4.9×10e^−5^ (6.9×10e^−20^--3.7×10e[@b10-cmar-10-5313])   0.57
   Yes                                                     195                100         95           0.673 (0.458--0.988)                      0.043   0.676 (0.425--1.075)                                     0.098
  Tumor size[b](#tfn7-cmar-10-5313){ref-type="table-fn"}                                                                                                                                                          
   ≤5 cm                                                   137                63          74           0.705 (0.437--1.136)                      0.151   0.575 (0.306--1.081)                                     0.086
   \>5 cm                                                  74                 42          32           0.570 (0.292--1.114)                      0.1     0.757 (0.363--1.579)                                     0.458
  Multinodular                                                                                                                                                                                                    
   Single                                                  167                81          86           0.618 (0.406--0.939)                      0.024   0.524 (0.309--0.888)                                     0.016
   Multiple                                                45                 25          20           0.837 (0.305--2.298)                      0.73    1.575 (0.533--4.659)                                     0.411
  BCLC stage                                                                                                                                                                                                      
   0                                                       20                 9           11           0.592 (0.101--3.457)                      0.561   7×10e^−6^ (2.64×10e^−264^--1.7×10e^245^)                 0.968
   A                                                       143                65          78           0.755 (0.475--1.199)                      0.234   0.684 (0.385--1.216)                                     0.196
   B                                                       22                 14          8            0.473 (0.123--1.815)                      0.275   1.006 (0.238--4.263)                                     0.993
   C                                                       27                 18          9            0.893 (0.291--2.734)                      0.842   0.981 (0.312--3.083)                                     0.973
  TNM stage                                                                                                                                                                                                       
   I                                                       89                 37          52           0.533 (0.266--1.068)                      0.076   0.553 (0.223--1.372)                                     0.201
   II                                                      76                 39          37           0.807 (0.438--1.488)                      0.492   0.987 (0.472--2.064)                                     0.973
   III                                                     47                 30          17           1.057 (0.459--2.435)                      0.897   1.081 (0.440--2.655)                                     0.866
  CLIP stage                                                                                                                                                                                                      
   0                                                       94                 40          54           0.827 (0.455--1.503)                      0.532   0.735 (0.330--1.639)                                     0.452
   1                                                       71                 35          36           0.681 (0.340--1.364)                      0.278   0.509 (0.218--1.189)                                     0.119
   2/3/4/5                                                 47                 31          16           0.411 (0.159--1.061)                      0.066   0.978 (0.391--2.448)                                     0.962
  Serum AFP[c](#tfn8-cmar-10-5313){ref-type="table-fn"}                                                                                                                                                           
   ≤300 ng/mL                                              115                52          63           0.860 (0.516--1.432)                      0.562   0.737 (0.386--1.405)                                     0.354
   \>300 ng/mL                                             94                 53          41           0.422 (0.232--0.767)                      0.005   0.512 (0.259--1.016)                                     0.055

**Notes:**

Adjustment for age, gender, cirrhosis, tumor size, tumor number, BCLC stage, and serum AFP level.

Information of tumor size was unavailable in one patient.

Information of serum AFP was unavailable in three patients.

**Abbreviations:** AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; CLIP, Cancer of the Liver Italian Program; ERCC, excision repair cross-complementation; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; OS, overall survival; RFS, recurrence-free survival.

###### 

Joint effect survival analysis of *ERCC8* and serum AFP in HBV-related HCC prognosis

  Group        AFP level[a](#tfn10-cmar-10-5313){ref-type="table-fn"}   ERCC8 expression   Patients (n=209)   MRT/MST (months)   Crude HR (95% CI)      Crude *P*   Adjusted HR (95% CI)   Adjusted *P*[b](#tfn11-cmar-10-5313){ref-type="table-fn"}
  ------------ -------------------------------------------------------- ------------------ ------------------ ------------------ ---------------------- ----------- ---------------------- -----------------------------------------------------------
                                                                                                                                                                                           
  **RFS**      **Serum (ng/mL**)                                                                              **MRT**                                                                      
   Group A     \>300                                                    Low                53                 23                 1                                  1                      
   Group B     \>300                                                    High               41                 NA                 0.448 (0.252--0.795)   0.006       0.426 (0.237--0.768)   0.004
   Group C     \<300                                                    Low                52                 48                 0.671 (0.414--1.086)   0.104       0.656 (0.398--1.081)   0.098
   Group D     \<300                                                    High               63                 51                 0.546 (0.340--0.877)   0.012       0.583 (0.354--0.962)   0.035
  **OS**                                                                                                      **MST**                                                                      
   Group a     \>300                                                    Low                53                 36                 1                                  1                      
   Group b     \>300                                                    High               41                 NA                 0.463 (0.242--0.889)   0.021       0.522 (0.268--1.018)   0.057
   Group c     \<300                                                    Low                52                 NA                 0.575 (0.329--1.005)   0.052       0.661 (0.369--1.185)   0.165
   Group d     \<300                                                    High               63                 NA                 0.401 (0.223--0.719)   0.002       0.499 (0.268--0.927)   0.028
  **RFS**      **mRNA**                                                                                       **MRT**                                                                      
   Group I     High                                                     Low                60                 21                 1                                  1                      
   Group II    High                                                     High               46                 NA                 0.389 (0.224--0.673)   0.001       0.418 (0.238--0.734)   0.002
   Group III   Low                                                      Low                46                 51                 0.519 (0.313--0.859)   0.011       0.425 (0.238--0.757)   0.004
   Group IV    Low                                                      High               60                 53                 0.524 (0.331--0.830)   0.006       0.443 (0.259--0.757)   0.003
  **OS**                                                                                                      **MST**                                                                      
   Group i     High                                                     Low                60                 47                 1                                  1                      
   Group ii    High                                                     High               46                 NA                 0.400 (0.206--0.775)   0.007       0.533 (0.267--1.063)   0.074
   Group iii   Low                                                      Low                46                 NA                 0.602 (0.339--1.069)   0.083       0.612 (0.308--1.215)   0.161
   Group iv    Low                                                      High               60                 NA                 0.478 (0.272--0.841)   0.01        0.487 (0.249--0.952)   0.035

**Notes:**

Information of serum AFP was unavailable in three patients.

Adjustment for age, gender, cirrhosis, tumor size, tumor number, BCLC stage, and serum AFP level.

**Abbreviations:** AFP, alpha-fetoprotein; ERCC, excision repair cross-complementation; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; MRT, median recurrence time; MST, median survival time; OS, overall survival; RFS, recurrence-free survival.
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